Neuland Laboratories Limited (NSE:NEULANDLAB)
India · Delayed Price · Currency is INR | Market Cap | 252.21B +14.6% |
| Revenue (ttm) | 23.14B +50.9% |
| Net Income | 4.53B +88.4% |
| EPS | 352.74 +88.5% |
| Shares Out | n/a |
| PE Ratio | 55.62 |
| Forward PE | 46.90 |
| Dividend | 34.00 (0.17%) |
| Ex-Dividend Date | Jul 24, 2026 |
| Volume | 148,362 |
| Open | 18,501 |
| Previous Close | 19,424 |
| Day's Range | 18,501 - 19,850 |
| 52-Week Range | 11,500 - 24,225 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | 24,828.50 (+26.55%) |
| Earnings Date | Nov 3, 2026 |
About Neuland Laboratories
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2026, Neuland Laboratories's revenue was 20.23 billion, an increase of 36.98% compared to the previous year's 14.77 billion. Earnings were 3.64 billion, an increase of 39.94%.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NEULANDLAB stock is "Strong Buy." The 12-month stock price target is ₹24,829, which is an increase of 26.55% from the latest price.
News
Neuland Laboratories Transcript: Q2 26/27
Q2 earnings fell below recent trends as commercial shipments remained uneven, while H1 was in line with expectations. Growth is still expected in FY27–FY28, supported by strong RFP activity and investments in peptides and process capabilities.
Neuland Laboratories Quarterly report: Q2 2027
Neuland Laboratories has published its Q2 2027 quarterly earnings report on November 3, 2026.
Neuland Laboratories Slides: Q2 2027
Neuland Laboratories has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 3, 2026.
Gland Pharma, Neuland enter into long-term sterile API CDMO partnership
Gland Pharma and Neuland Labs form long-term sterile API CDMO partnership; new cGMP/FDA/EU suite at Visakhapatnam JNPC adds ~1,400 kg/year capacity.
Neuland Laboratories Transcript: Q1 26/27
Q1 FY 2027 saw revenue more than double year-over-year, with strong profitability and improved working capital efficiency. Growth was driven by commercial CMS projects, expanding peptide capabilities, and strategic investments, while management maintains a positive outlook for FY 2027 and FY 2028 despite expected business lumpiness.
Neuland Laboratories Quarterly report: Q1 2027
Neuland Laboratories has published its Q1 2027 quarterly earnings report on August 5, 2026.
Neuland Laboratories Slides: Q1 2027
Neuland Laboratories has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
Neuland Laboratories announces Rs 34 per share dividend and appoints new director
Neuland Laboratories has reported several key decisions following its recent board meeting. The company has approved a final dividend of ₹34 per equity share, representing a 340% return on a…
Neuland Laboratories Transcript: Q4 25/26
Q4 and FY 2026 saw record revenue and profit growth, driven by CMS segment and strong margins, despite higher working capital and CapEx. Management expects continued lumpy but robust growth, with strategic investments in peptides and R&D supporting long-term prospects.
Neuland Laboratories Quarterly report: Q4 2026
Neuland Laboratories has published its Q4 2026 quarterly earnings report on May 12, 2026.
Neuland Laboratories Slides: Q4 2026
Neuland Laboratories has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 12, 2026.
Neuland Laboratories Annual report: Q4 2026
Neuland Laboratories has published its Q4 2026 annual report on May 12, 2026.
Neuland Laboratories announces Rs 34 per share final dividend and capacity expansion
Neuland Laboratories has declared a final dividend of ₹34 per share for the financial year 2025-26, representing a 340% payout on the face value of ₹10 per share. The dividend…
Neuland Laboratories reports Rs 2053.1 crore total income for FY26
Neuland Laboratories Limited (NSE: NEULANDLAB), a leading pharmaceutical manufacturer, has announced its financial results for the fiscal year ending March 31, 2026. The company reported a total incom...
Neuland Laboratories reports Rs 2053.1 crore total income for Q4 FY26
Neuland Laboratories Limited has announced its financial results for the fourth quarter and the fiscal year ending March 31, 2026, reporting a total income of ₹2053.1 crore. The pharmaceutical company...
Neuland Laboratories Q4 Results: Net profit jumps 664% YoY to Rs 212.67 crore, revenue surges 136%
Neuland Laboratories reported a blockbuster performance for the fourth quarter ended March 2026, with sharp growth in revenue and profitability on a year-on-year basis. The company posted consolidated...
Neuland Laboratories appoints Saharsh Davuluri as CEO & MD to spearhead CDMO expansion
Neuland Laboratories has announced a significant leadership change with Saharsh Davuluri taking over as the Chief Executive Officer and Managing Director. This transition marks a new chapter for the c...
Pharma sector stocks today, Feb 17: Akums Drugs jumps 5%, Indegene up 4.29%, Neuland Labs surge 4.03%
The pharmaceutical sector stocks in India showed mixed performance on February 17, 2026, during early morning trading hours. Data is...
Neuland Laboratories Transcript: Q3 25/26
Q3 FY26 revenue grew 11.4% year-over-year, driven by CMS projects, but gross margin declined to 52.1% due to product mix and absence of high-margin products. Management remains optimistic about medium-term growth, supported by capacity expansion, new CMS molecules, and upcoming peptide facility commissioning.
Neuland Laboratories Quarterly report: Q3 2026
Neuland Laboratories has published its Q3 2026 quarterly earnings report on February 9, 2026.
Neuland Laboratories Slides: Q3 2026
Neuland Laboratories has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 9, 2026.
Neuland Labs shares jump over 7% after stellar Q2 results: Net profit surges nearly 3x YoY
Neuland Laboratories Ltd saw its shares rally more than 7% in early trade on Monday after the company delivered a...
Neuland Labs share: Nuvama maintains buy, sees 24.5% upside after strong Q2 beat and robust CMS growth
Nuvama Institutional Equities has maintained its buy call on Neuland Laboratories Ltd and raised the target price to ₹22,130 per...
[Brokerage calls] Stocks to watch today, Nov 10, 2025: Trent, Nykaa, Bajaj Auto, Hindalco, Chola Investment, Lupin, PFC, NCC, Divi’s Labs and Neuland Labs in focus
Asian markets began the week on a steady note, with a flurry of brokerage actions setting the tone for key...
Neuland Laboratories Transcript: Q2 25/26
Q2 FY2026 saw a 63.7% revenue increase to INR 516 crore, driven by CMS projects and improved margins. Strong growth is expected for FY2026, with ongoing investments in peptide capabilities and new manufacturing capacity supporting future expansion.